Qyuns Therapeutics Co., Ltd. 2025 Annual Report: Key Financial and Corporate Highlights for Investors

Overview

Qyuns Therapeutics Co., Ltd. has released its 2025 Annual Report, revealing a year of remarkable financial turnaround, robust operational performance, and several corporate actions that could significantly impact shareholder value and the company’s stock price. Investors are urged to review the following details for a comprehensive understanding of the company’s current position and future prospects.

Highlights of Financial Performance

• Revenue Surge: Revenue soared to RMB 806.96 million in 2025, a five-fold increase from RMB 158.79 million in 2024, reflecting successful commercialization and licensing activities.
• Return to Profitability: The company reported a profit of RMB 307.44 million for 2025, a dramatic turnaround from the loss of RMB 349.69 million in 2024.
• Gross Profit Margin Expansion: Gross profit reached RMB 714.41 million versus RMB 92.19 million last year, with gross margins improving due to higher licensing and product sales.
• Reduction in R&D Expenditure: Research and development expenses fell to RMB 253.17 million, down from RMB 334.28 million, indicating completion of key development milestones and refocusing investment.
• Distribution and Selling Expenses: Increased to RMB 30.59 million, primarily due to commission fees from licensing-out deals.
• Cash and Financial Assets: Cash and equivalents, time deposits, and financial assets measured at FVPL increased 87.4% to RMB 1,041.97 million, mainly due to milestone payments from QX030N, QX031N, and QX005N, share placement proceeds, and bank borrowings.
• Adjusted Profit: Excluding share-based compensation, adjusted profit for 2025 was RMB 356.20 million, compared to an adjusted loss of RMB 274.23 million in 2024.

Corporate Actions and Shareholder Updates

• Share Repurchase: The company repurchased 1,512,000 H Shares for HK\$29.91 million, holding them as treasury shares. This action can support share value and signals management’s confidence in the company’s prospects.
• Capital Structure: Total issued shares as of year-end were 227,071,600, including treasury shares.
• No Final Dividend: The Board does not recommend a final dividend for 2025, suggesting reinvestment in growth and R&D over shareholder payouts.
• Share Placement: The company raised RMB 91 million net proceeds from placement of new H Shares, strengthening liquidity and funding for future projects.
• Change in Use of Proceeds: Remaining proceeds originally allocated to completed R&D projects have been reallocated to a new pipeline project, QX027N, reflecting strategic adjustments and further focus on core assets.
• Material Litigation: No material legal proceedings during the year, reducing risk exposure.
• Compliance and Governance: No material breaches of laws or regulations. The company confirms compliance with all Listing Rules and maintains robust corporate governance, including audit committee oversight and risk management policies.
• Connected Transactions: Several connected transactions with Zhongmei Huadong exceeded 5% of applicable ratios, requiring independent shareholder approval. All such transactions were approved and reviewed by independent directors and auditors, confirming fairness and compliance.
• Environmental, Social, and Governance (ESG): No material incidents or complaints affecting operations; continued commitment to sustainability and employee welfare.

Risk Factors

• Credit Risk: 53.1% of trade receivables are due from the five largest debtors, with ongoing monitoring and impairment assessment.
• Liquidity Risk: The group maintains sufficient cash reserves and funding lines to meet short- and long-term liquidity needs.
• Currency and Interest Rate Risks: The company is exposed to fluctuations in USD and HKD, with sensitivity analyses showing material potential impacts on profit/loss.
• Shareholder Structure: No pre-emptive rights; substantial shareholders and directors’ interests disclosed, with Mr. Qiu holding approximately 4.40% of total shares.

Strategic Developments and Outlook

• Pipeline Focus: Strategic shift to allocate resources to QX027N and other core pipeline projects, aiming to optimize returns and accelerate innovation.
• Future Plans: No current plans for material investments, acquisitions, or disposals, except as previously disclosed regarding use of proceeds from offerings and placements.
• Dividend Policy: No predetermined payout ratio; dividends depend on financial condition, statutory reserves, and shareholder approval.

Potential Share Price Sensitivities

• Strong Profit Recovery: The swing from loss to profit, alongside revenue growth, is likely to attract investor attention and could positively impact the share price.
• Share Repurchase: Management’s action to buy back shares supports the market value and signals confidence, potentially reducing supply and increasing demand.
• Strategic Pipeline Shift: Reallocation of R&D funds to new projects may be viewed positively if QX027N delivers on its promise, but also introduces execution risk.
• Robust Liquidity and Cash Position: Enhanced cash and asset reserves provide financial flexibility for growth and resilience against future uncertainties.
• Connected Transactions Approval: Successful shareholder approval for large connected transactions may enhance confidence in corporate transparency and governance.

Important Notices for Shareholders

• No Final Dividend for 2025: Investors should note the absence of a final dividend, which may affect income expectations.
• Share Repurchases: Repurchased shares are held as treasury shares for potential future use, not cancelled.
• Change in Use of Proceeds: Shareholders are to approve the reallocation at the upcoming AGM; this is a significant strategic decision.
• Environmental and Social Commitments: The company upholds ESG standards with no material adverse events reported.
• Amendments to Articles of Association: Changes have been made and published; shareholders should review the updated documents for implications.

Conclusion

Qyuns Therapeutics Co., Ltd. delivered a year of exceptional financial recovery, strategic realignment, and corporate actions that are highly relevant to investors. The combination of strong revenue growth, return to profitability, share repurchases, pipeline refocus, and transparent governance practices make the 2025 Annual Report a pivotal document for current and potential shareholders. These developments are likely to influence the company’s share price and warrant close investor attention.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The information is based on the company’s published annual report and may be subject to change. Investors should conduct their own research and consult professional advisors before making investment decisions.

View QYUNS-B Historical chart here